ATE374252T1 - Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen - Google Patents

Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen

Info

Publication number
ATE374252T1
ATE374252T1 AT96420265T AT96420265T ATE374252T1 AT E374252 T1 ATE374252 T1 AT E374252T1 AT 96420265 T AT96420265 T AT 96420265T AT 96420265 T AT96420265 T AT 96420265T AT E374252 T1 ATE374252 T1 AT E374252T1
Authority
AT
Austria
Prior art keywords
sequence
sequences
pol
partial
multiple sclerosis
Prior art date
Application number
AT96420265T
Other languages
English (en)
Inventor
Herve Perron
Glaucia Paranhos-Baccala
Frederic Beseme
Florence Komurian-Pradel
Frederic Bedin
Colette Jolivet-Reynaud
Bernard Mandrand
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Application granted granted Critical
Publication of ATE374252T1 publication Critical patent/ATE374252T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
AT96420265T 1995-08-03 1996-08-02 Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen ATE374252T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9509643A FR2737500B1 (fr) 1995-08-03 1995-08-03 Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Publications (1)

Publication Number Publication Date
ATE374252T1 true ATE374252T1 (de) 2007-10-15

Family

ID=9481811

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07018564T ATE541933T1 (de) 1995-08-03 1996-08-02 Antigene polypeptide, die mit multipler sklerose assoziiert sind, und verwendungszwecke
AT96420265T ATE374252T1 (de) 1995-08-03 1996-08-02 Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07018564T ATE541933T1 (de) 1995-08-03 1996-08-02 Antigene polypeptide, die mit multipler sklerose assoziiert sind, und verwendungszwecke

Country Status (19)

Country Link
US (4) US6001987A (de)
EP (2) EP1916304B1 (de)
JP (2) JP4444372B2 (de)
AT (2) ATE541933T1 (de)
AU (1) AU730080B2 (de)
BG (1) BG62977B1 (de)
BR (1) BR9606566A (de)
CA (1) CA2201282C (de)
CZ (1) CZ135797A3 (de)
DE (1) DE69637264T2 (de)
ES (2) ES2293645T3 (de)
FR (1) FR2737500B1 (de)
HU (1) HUP9900425A3 (de)
IS (1) IS4455A (de)
NO (1) NO971493L (de)
NZ (1) NZ316080A (de)
PL (1) PL319512A1 (de)
SK (1) SK56797A3 (de)
WO (1) WO1997006260A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP0938320B2 (de) * 1996-03-26 2014-06-18 Michael S. Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
JP4044142B2 (ja) * 1996-10-04 2008-02-06 ビー． アーノビッツ，ハワード 核酸の診断検出
ES2331496T3 (es) * 1996-11-26 2010-01-05 Bio Merieux Material viral y fragmentos de nucleotidos asociados a la esclerosis multiple, para fines diagnosticos, profilacticos y terapeuticos.
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
FR2762600B1 (fr) * 1997-04-29 1999-11-05 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utlisations
FR2762601B3 (fr) * 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
FR2765588A1 (fr) * 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
EP1000158B1 (de) * 1997-07-07 2006-11-22 Bio Merieux Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen
US20040176314A1 (en) * 1997-07-07 2004-09-09 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
WO1999053103A1 (en) * 1998-04-08 1999-10-21 Ms Research A/S Diagnosis of multiple sclerosis and other demyelinating diseases
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
FR2788784A1 (fr) * 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (de) 1999-02-15 2000-08-23 Bio Merieux Die LTR-Region von MSRV und die durch sie kodierten Proteine, und Sonden und Methoden für Detektion des MSRV-1 Retrovirus
AU6785700A (en) * 1999-08-20 2001-03-19 Biogen, Inc. Novel polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
DE10012875B4 (de) * 2000-03-16 2004-04-01 Infineon Technologies Ag Mobilfunkempfänger
EP1265989A2 (de) * 2000-03-21 2002-12-18 MS Research A/S Infectiöses endogenes retrovirus und ihre korrelation mit demyelinierender krankheiten z.b. multipel sklerose
DE60239470D1 (de) * 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871996A (en) * 1994-02-04 1999-02-16 Bio Merieux Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
US4346074A (en) * 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (de) * 1988-01-29 1989-08-02 City Of Hope Verfahren zum Nachweis und zur Identifizierung von bestimmten viralen Sequenzien
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
EP0642585B1 (de) * 1992-05-18 2005-12-28 Genentech, Inc. Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
US5691147A (en) * 1994-06-02 1997-11-25 Mitotix, Inc. CDK4 binding assay
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques

Also Published As

Publication number Publication date
NO971493L (no) 1997-06-03
US20070117189A1 (en) 2007-05-24
US7932350B2 (en) 2011-04-26
EP0789077B1 (de) 2007-09-26
AU6823296A (en) 1997-03-05
AU730080B2 (en) 2001-02-22
HUP9900425A2 (hu) 1999-05-28
WO1997006260A1 (fr) 1997-02-20
HUP9900425A3 (en) 1999-11-29
DE69637264T2 (de) 2008-06-26
NO971493D0 (no) 1997-04-02
CA2201282A1 (fr) 1997-02-20
CZ135797A3 (cs) 1998-06-17
US20030186391A1 (en) 2003-10-02
IS4455A (is) 1997-03-26
EP1916304B1 (de) 2012-01-18
EP1916304A2 (de) 2008-04-30
ES2293645T3 (es) 2008-03-16
DE69637264D1 (de) 2007-11-08
JP4444372B2 (ja) 2010-03-31
JP5143814B2 (ja) 2013-02-13
BR9606566A (pt) 1997-12-30
PL319512A1 (en) 1997-08-18
JPH11502416A (ja) 1999-03-02
ES2379011T3 (es) 2012-04-19
EP1916304A3 (de) 2008-05-07
FR2737500A1 (fr) 1997-02-07
SK56797A3 (en) 1998-09-09
FR2737500B1 (fr) 1997-08-29
EP0789077A1 (de) 1997-08-13
ATE541933T1 (de) 2012-02-15
US6001987A (en) 1999-12-14
BG62977B1 (bg) 2000-12-29
BG101355A (en) 1997-12-30
NZ316080A (en) 1999-04-29
US6579526B1 (en) 2003-06-17
CA2201282C (fr) 2013-04-02
JP2010047604A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
ATE374252T1 (de) Virales material und multiple-sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen
Saltarelli et al. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus
Ono et al. Nucleotide sequence of the Syrian hamster intracisternal A-particle gene: close evolutionary relationship of type A particle gene to types B and D oncovirus genes
Watson et al. Nucleotide sequence analysis of human c-myc locus, chicken homologue, and myelocytomatosis virus MC29 transforming gene reveals a highly conserved gene product.
AU692163B2 (en) Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells
JP2019522461A5 (de)
Buzdin et al. Friends-enemies: endogenous retroviruses are major transcriptional regulators of human DNA
Böhnlein et al. Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat
NO951307L (no) Terapeutiske anti-HIV oligonukleotider
DE69033896D1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
US5580703A (en) Human adeno-associated virus integration site DNA and uses thereof
Wachsman et al. HTLV x-gene product: requirement for the env methionine initiation codon
Rethwilm et al. Molecular cloning of the genome of human spumaretrovirus
Kovalskaya et al. Functional human endogenous retroviral LTR transcription start sites are located between the R and U5 regions
HUP9800260A1 (hu) Eljárás rekombináns adenovírus előállítására és génterápiai alkalmazása
Mager Polyadenylation function and sequence variability of the long terminal repeats of the human endogenous retrovirus-like family RTVL-H
GB9310657D0 (en) Retrovirus
US20090061488A1 (en) Method of synthesizing a target polynucleotide encoding a protein
Fang et al. Integration of HTLV-1 provirus into mouse transforming growth factor-α gene
AU8545098A (en) Retroviral nucleic material and nucleotide fragments, in particular associated with multiple sclerosis and/or rheumatoid arthritis, for diagnostic, prophylacticand therapeutic uses
MY104975A (en) Protease, reverse transcriptase and endonuclease of retrovirus, and method for producing these enzymes.
ATE135404T1 (de) Nukleinsäurefragmente und vom hhv6/sie virusgenom abgeleitete diagnosemittel sowie verfahren zur diagnose von hhv6 infektionen
US20050069899A1 (en) Method of synthesizing a target polynucleotide efficiently expressed in a host-vector expression system
Dietz et al. Use of primer pools for specific gene amplification.
Clements Genetic regulation of the ungulate lentiviruses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties